On Wednesday, Washington headquartered OncoGenex Pharmaceuticals Inc.'s stock recorded a trading volume of 76,557 shares, and ended the session 1.14% higher at $0.56. The Company's shares have gained 11.13% in the last one month, 50.58% in the previous three months, and 11.48% on an YTD basis. The stock is trading 9.11% above its 50-day moving average. Moreover, shares of OncoGenex Pharma, which develops and commercializes therapies that address treatment resistance in cancer patients, have a Relative Strength Index (RSI) of 51.35.
On January 05th, 2017, OncoGenex Pharma and Achieve Life Science, Inc., a privately held specialty pharmaceutical company, announced that they have entered into a definitive merger agreement. Upon completion of the proposed merger, Achieve Life Science's equity holders are expected to own 75% of the combined Company's outstanding shares and current OncoGenex's stockholders are expected to own the remaining 25% of the combined Company's outstanding shares. Following completion of the merger, OncoGenex Pharma will be renamed Achieve Life Sciences, Inc. Your complete research report on OGXI can be retrieved for free at:
Chandler, Arizona headquartered INSYS Therapeutics Inc.'s stock closed the day 1.50% lower at $9.85. A total volume of 1.16 million shares was traded, which was above their three months average volume of 908,950 shares. The Company's shares have advanced 8.48% in the past month and 7.07% since the start of this year. The stock is trading 8.98% below its 50-day moving average. Additionally, shares of INSYS Therapeutics, which develops and commercializes supportive care products, have an RSI of 42.88.
On January 09th, 2017, Insys Therapeutics announced that Dr. John N. Kapoor, its Founder, President, CEO, and also Chairman of the Company's Board of Directors will retire as President and CEO and Chairman effective January 09th, 2017. Dr. Kapoor will remain a member of the Board and will Chair the newly formed Science and Research and Development Committee of the Board. In connection with Dr. Kapoor's retirement, the Board has appointed Dr. Santosh Vetticaden as Interim CEO and Steven Meyer as Chairman of the Board, effective January 09th, 2017. A free report on INSY is just a click away at:
Shares in South San Francisco, California headquartered Threshold Pharmaceuticals Inc. recorded a trading volume of 194,197 shares, and ended yesterday's trading session 0.75% lower at $0.50. The stock has advanced 9.07% in the past month, 16.67% over the previous three months, and 14.02% on an YTD basis. The Company's shares are trading above their 50-day moving average by 4.44%. Furthermore, shares of Threshold Pharma, which discovers and develops therapeutic agents that target tumor cells for the treatment of cancer patients in the US, have an RSI of 53.75.
On December 19th, 2016, Threshold Pharmaceuticals announced that it has entered into a collaboration with the National Cancer Institute (NCI), part of the National Institutes of Health, to study TH-3424, the Company's new drug candidate for the treatment of cancer. The collaboration will explore the effects of TH-3424 against T-cell acute lymphoblastic leukemia xenograft cell lines with high AKR1C3 expression. The studies will be conducted through the NCI-funded Pediatric Preclinical Testing Consortium. Sign up for your complimentary research report on THLD at:
San Diego, California-based AmpliPhi Biosciences Corp.'s stock finished Wednesday's session 0.33% higher at $0.46 with a total trading volume of 77,266 shares. The Company's shares have advanced 0.65% in the last one month and 5.23% since the start of this year. The stock is trading below its 50-day moving average by 15.98%. Additionally, shares of AmpliPhi Biosciences, which focuses on the discovery, development, and commercialization of various bacteriophage therapeutics, have an RSI of 44.53.
On December 19th, 2016, AmpliPhi Biosciences reported final results from its Phase-1 trial of AB-SA01, a proprietary investigational bacteriophage (phage) cocktail targeting Staphylococcus aureus infections, in patients with chronic rhinosinusitis. The Company stated that AB-SA01 met the trial's primary endpoints of safety and tolerability and all nine patients enrolled in the study experienced a reduction in the quantity of S. aureus infecting their sinuses, with some patients showing complete eradication of the bacterial infection. Register for free on Stock-Callers.com and download the latest research report on APHB at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA